摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-Boc-哌啶 | 75844-69-8

中文名称
1-Boc-哌啶
中文别名
N-BOC-哌啶;N-叔丁氧羰基哌啶;叔丁基哌啶-1-甲酸酯;哌啶-1-甲酸叔丁酯;1-叔丁氧羰基哌啶
英文名称
t-butyl piperidinecarboxylate
英文别名
tert-butyl piperidine-1-carboxylate;N-Boc-piperidine;1-Boc-piperidine
1-Boc-哌啶化学式
CAS
75844-69-8
化学式
C10H19NO2
mdl
——
分子量
185.266
InChiKey
RQCNHUCCQJMSRG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    130-140°C 15mm
  • 密度:
    0.964 g/mL at 25 °C(lit.)
  • 闪点:
    188 °F
  • 稳定性/保质期:

    远离氧化物。

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    13
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.9
  • 拓扑面积:
    29.5
  • 氢给体数:
    0
  • 氢受体数:
    2

安全信息

  • 危险等级:
    IRRITANT, KEEP COLD
  • 危险品标志:
    T,N
  • 安全说明:
    S26,S36,S45,S60,S61
  • 危险类别码:
    R50,R36/37/38,R25
  • WGK Germany:
    3
  • 海关编码:
    2933399090
  • 危险品运输编号:
    UN 2810 6.1/PG 3
  • 包装等级:
    III
  • 危险类别:
    6.1
  • 危险性防范说明:
    P261,P273,P301+P310,P305+P351+P338
  • 危险性描述:
    H227,H301,H315,H319,H335,H410
  • 储存条件:
    存放在密封容器中,并置于阴凉、干燥处。请远离氧化剂。建议冷藏保存。

SDS

SDS:4453d8d960787ff2b7eadb203ddcef6e
查看

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : N-Boc-piperidine
CAS-No. : 75844-69-8
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances



Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP]
Acute toxicity, Oral (Category 3)
Skin irritation (Category 2)
Eye irritation (Category 2)
Specific target organ toxicity - single exposure (Category 3)
Acute aquatic toxicity (Category 1)
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Toxic if swallowed. Irritating to eyes, respiratory system and skin. Very toxic to aquatic organisms.
Label elements
Labelling according Regulation (EC) No 1272/2008 [CLP]
Pictogram
Signal word Danger
Hazard statement(s)
H301 Toxic if swallowed.
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
H400 Very toxic to aquatic life.
Precautionary statement(s)
P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
P273 Avoid release to the environment.
P301 + P310 IF SWALLOWED: Immediately call a POISON CENTER or doctor/
physician.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
According to European Directive 67/548/EEC as amended.
Hazard symbol(s)
R-phrase(s)
R25 Toxic if swallowed.
R36/37/38 Irritating to eyes, respiratory system and skin.
R50 Very toxic to aquatic organisms.
S-phrase(s)
S26 In case of contact with eyes, rinse immediately with plenty of water and
seek medical advice.
S36 Wear suitable protective clothing.
S45 In case of accident or if you feel unwell, seek medical advice immediately
(show the label where possible).
S60 This material and its container must be disposed of as hazardous waste.
S61 Avoid release to the environment. Refer to special instructions/ Safety
data sheets.
Other hazards - none

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Synonyms : 1-Boc-piperidine
N-(tert-Butoxycarbonyl)piperidine
N-Boc-tetrahydropyridine
Formula : C10H19NO2
Molecular Weight : 185,26 g/mol
Component Concentration
N-Boc-piperidine
CAS-No. 75844-69-8 -

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Take victim immediately to hospital. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Do NOT induce vomiting. Never give anything by mouth to an unconscious person. Rinse mouth with
water. Consult a physician.
Most important symptoms and effects, both acute and delayed
Indication of any immediate medical attention and special treatment needed
no data available

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
For small (incipient) fires, use media such as "alcohol" foam, dry chemical, or carbon dioxide. For large
fires, apply water from as far as possible. Use very large quantities (flooding) of water applied as a mist or
spray; solid streams of water may be ineffective. Cool all affected containers with flooding quantities of
water.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx)
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
Use water spray to cool unopened containers.

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Wear respiratory protection. Avoid breathing vapors, mist or gas. Ensure adequate ventilation. Remove
all sources of ignition. Evacuate personnel to safe areas. Beware of vapours accumulating to form
explosive concentrations. Vapours can accumulate in low areas.
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into the
environment must be avoided.
Methods and materials for containment and cleaning up
Contain spillage, and then collect with an electrically protected vacuum cleaner or by wet-brushing and
place in container for disposal according to local regulations (see section 13). Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid inhalation of vapour or mist.
Keep away from sources of ignition - No smoking.Take measures to prevent the build up of electrostatic
charge.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place. Containers which are
opened must be carefully resealed and kept upright to prevent leakage.
Specific end uses
no data available

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling
the product.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face respirator
with multi-purpose combination (US) or type ABEK (EN 14387) respirator cartridges as a backup
to engineering controls. If the respirator is the sole means of protection, use a full-face supplied air
respirator. Use respirators and components tested and approved under appropriate government
standards such as NIOSH (US) or CEN (EU).

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: liquid
Colour: colourless
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and 60 - 65 °C at 1 hPa
boiling range
g) Flash point 86 °C - closed cup
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density 0,964 g/cm3 at 25 °C
n) Water solubility no data available
o) Partition coefficient: n- log Pow: 2,419
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
Heat, flames and sparks.
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Inhalation: no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
Inhalation - May cause respiratory irritation.
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. Causes respiratory tract irritation.
Ingestion Toxic if swallowed.
Skin May be harmful if absorbed through skin. Causes skin irritation.
Eyes Causes serious eye irritation.
Additional Information
RTECS: Not available

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
Very toxic to aquatic life.

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
This combustible material may be burned in a chemical incinerator equipped with an afterburner and
scrubber. Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material.
Contaminated packaging
Dispose of as unused product.

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: 2810 IMDG: 2810 IATA: 2810
UN proper shipping name
ADR/RID: TOXIC LIQUID, ORGANIC, N.O.S. (N-Boc-piperidine)
IMDG: TOXIC LIQUID, ORGANIC, N.O.S. (N-Boc-piperidine)
IATA: Toxic liquid, organic, n.o.s. (N-Boc-piperidine)
Transport hazard class(es)
ADR/RID: 6.1 IMDG: 6.1 IATA: 6.1
Packaging group
ADR/RID: III IMDG: III IATA: III
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

Section 15. REGULATORY INFORMATION
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment
no data available

Section 16. OTHER INFORMATION
Further information
Copyright 2011 Co. License granted to make unlimited paper copies for internal use only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Co., shall not be held liable for any damage
resulting from handling or from contact with the above product. See reverse side of invoice or packing
slip for additional terms and conditions of sale.

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2
    • 3
    • 4
    • 5

反应信息

  • 作为反应物:
    描述:
    1-Boc-哌啶硫酸 、 sodium chloride 作用下, 以 neat (no solvent) 为溶剂, 反应 1.0h, 以99%的产率得到哌啶盐酸盐
    参考文献:
    名称:
    通过异位生成氯化氢气体进行无溶剂 N-Boc 脱保护
    摘要:
    描述了一种有效、可扩展且可持续的方法,用于在无溶剂条件下使用低至接近化学计量的氯化氢气体对氨基甲酸叔丁酯 ( N -Boc) 保护基团进行定量脱保护。我们展示了在两室反应器中从氯化钠和硫酸异位生成氯化氢气体,介绍了一种用于控制和化学计量释放 HCl 气体的简单方法。无溶剂条件允许对多种N进行脱保护-Boc衍生物以定量产率获得盐酸盐。该程序消除了对任何后处理或纯化步骤的需要,为标准方法提供了一种简单的绿色替代方案。由于无溶剂、无水条件,该方法对酸敏感官能团具有高耐受性,并提供扩展的官能团正交性。
    DOI:
    10.1039/d1ob00728a
  • 作为产物:
    描述:
    1-Boc-2-哌啶酮二异丁基氢化铝 作用下, 以 四氢呋喃 为溶剂, 生成 1-Boc-哌啶
    参考文献:
    名称:
    设计,合成,抗病毒活性,和结构-活性关系(SARs)的两种类型的结构上新型的菲咯啉/喹喔啉类似物。
    摘要:
    为了研究天然菲咯菌素/喹喔啉生物碱的原始骨架变化对抗病毒活性的影响,设计,合成并评估了两种类型的结构新颖的类似物7a,7b,16a和16b,以抵抗烟草花叶病毒(TMV)。首次。生物测定结果表明,所有四个新设计的类似物均表现出良好的抗病毒活性,其中类似物16a与宁南霉素(可能是最成功的商业抗病毒药物之一)相比,其活性降低了,因此逐渐成为植物病毒的潜在抑制剂,并成为进一步优化的新途径。还讨论了进一步的构效关系,这首次证明菲咯啉吲哚和菲咯啉喹嗪的原始骨架的相同变化表现出完全不同的抗病毒活性,提供了一些有关维持高活性的优先构象的有用的原始信息。
    DOI:
    10.1021/jf405562r
  • 作为试剂:
    描述:
    4-碘苯甲醚氰化亚铜 在 bis-triphenylphosphine-palladium(II) chloride 、 四甲基乙二胺仲丁基锂1-Boc-哌啶 作用下, 生成 4-甲氧基苯甲腈tert-butyl 2-(4-methoxyphenyl)piperidine-1-carboxylate
    参考文献:
    名称:
    Copper Cyanide-Catalyzed Palladium Coupling of N-tert-Butoxycarbonyl-Protected α-Lithio Amines with Aryl Iodides or Vinyl Iodides
    摘要:
    Treatment of (alpha-aminoalkyl)lithium reagents with aryl iodides in the presence of catalytic amounts of CuCN and PdCl2(PPh3)(2) or [(p-MeOC6H4)(3)P](4)Pd affords 2-aryl substituted amines in modest to good yields. The yields can be improved by use of softer ligands such as AsPh3 and SbPh3 or by use of bis(diphenylphosphino)ferrocene (dppf). Coupled products are obtained with electron-rich aryl iodides (XArI, X = Me, OMe), and the reaction fails with electron-poor aryl iodides (XArI, X = NO2, CO2Li). Treatment of the (alpha-aminoalkyl)lithium reagents with vinyl iodides and Pd(0)/dppf/CuCN afforded the coupling products in low to modest yields.
    DOI:
    10.1021/jo970985b
点击查看最新优质反应信息

文献信息

  • Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
    申请人:Vertex Pharmaceuticals Incorporated
    公开号:US20150231142A1
    公开(公告)日:2015-08-20
    The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.
    本发明涉及含有上皮通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物(A式、B式、C式或D式)的药物组合物。该发明还涉及这些药物配方,以及使用这些组合物治疗CFTR介导的疾病,特别是囊性纤维化的方法。
  • 1,1,1,3,3,3-Hexafluoroisopropanol: A Recyclable Organocatalyst for<i>N</i>-Boc Protection of Amines
    作者:Akbar Heydari、Samad Khaksar、Mahmood Tajbakhsh
    DOI:10.1055/s-2008-1067272
    日期:2008.10
    A simple and efficient protocol for the chemoselective mono-N-Boc protection of various structurally diverse amines with di-tert-butyl dicarbonate using 1,1,1,3,3,3-hexafluoroisopropanol (HFIP) as solvent and catalyst is described. The catalyst can be readily separated from the reaction products and recovered for direct reuse. No competitive side reactions such as formation of isocyanate, urea, and N,N-di-Boc were observed. α-Amino alcohols afforded the N-Boc derivatives without oxazolidinone formation.
    描述了一种简单且高效的化学选择性单-N-Boc保护多种结构多样性胺类的方法,使用二叔丁基二碳酸酯和1,1,1,3,3,3-六氟异丙醇(HFIP)作为溶剂和催化剂。催化剂可以轻易地从反应产物中分离并回收,以便直接重复使用。未观察到异氰酸酯和N,N-二-Boc等竞争性副反应。α-醇类在未形成恶唑烷酮的情况下获得了N-Boc衍生物
  • [EN] INHIBITORS OF BRUTON'S TYROSINE KINASE<br/>[FR] INHIBITEURS DE TYROSINE KINASE DE BRUTON
    申请人:BIOCAD JOINT STOCK CO
    公开号:WO2018092047A1
    公开(公告)日:2018-05-24
    The present invention relates to a new compound of formula I: or pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein: V1 is C or N, V2 is C(R2) or N, whereby if V1 is C then V2 is N, if V1 is C then V2 is C(R2), or if V1 is N then V2 is C(R2); each n, k is independently 0, 1; each R2, R11 is independently H, D, Hal, CN, NR'R", C(O)NR'R", C1-C6 alkoxy; R3 is H, D, hydroxy, C(O)C1-C6 alkyl, C(O)C2-C6 alkenyl, C(O)C2-C6 alkynyl, C1-C6 alkyl; R4 is H, Hal, CN, CONR'R", hydroxy, C1-C6 alkyl, C1-C6 alkoxy; L is CH2, NH, O or chemical bond; R1 is selected from the group of the fragments, comprising: Fragment 1, Fragment 2, Fragment 3 each A1, A2, A3, A4 is independently CH, N, CHal; each A5, A6, A7, A8, A9 is independently C, CH or N; R5 is H, CN, Hal, CONR'R", C1-C6 alkyl, non-substituted or substituted by one or more halogens; each R' and R" is independently selected from the group, comprising H, C1-C6 alkyl, C1-C6 cycloalkyl, aryl; R6 is selected from the group: [formula II] each R7, R8, R9, R10 is independently vinyl, methylacetylenyl; Hal is CI, Br, I, F, which have properties of inhibitor of Bruton's tyrosine kinase (Btk), to pharmaceutical compositions containing such compounds, and their use as pharmaceuticals for treatment of diseases and disorder.
    本发明涉及一种新的化合物,其化学式为I:或其药学上可接受的盐、溶剂化合物或立体异构体,其中:V1为C或N,V2为C(R2)或N,如果V1为C,则V2为N,如果V1为C,则V2为C(R2),或者如果V1为N,则V2为C(R2);每个n,k独立地为0或1;每个R2,R11独立地为H,D,Hal,CN,NR'R",C(O)NR'R",C1-C6烷氧基;R3为H,D,羟基,C(O)C1-C6烷基,C(O)C2-C6烯基,C(O)C2-C6炔基,C1-C6烷基;R4为H,Hal,CN,CONR'R",羟基,C1-C6烷基,C1-C6烷氧基;L为CH2,NH,O或化学键;R1从包括的片段组中选择:片段1,片段2,片段3,每个A1,A2,A3,A4独立地为CH,N,CHal;每个A5,A6,A7,A8,A9独立地为C,CH或N;R5为H,CN,Hal,CONR'R",C1-C6烷基,未取代或被一个或多个卤素取代;每个R'和R"独立地从包括H,C1-C6烷基,C1-C6环烷基,芳基的组中选择;R6从组中选择:[化学式II]每个R7,R8,R9,R10独立地为乙烯基,甲基乙炔基;Hal为CI,Br,I,F,具有布鲁顿酪氨酸激酶(Btk)抑制剂的性质,以及含有这种化合物的药物组合物,以及它们作为治疗疾病和紊乱的药物的用途。
  • Manganese-Catalyzed Desaturation of N-Acyl Amines and Ethers
    作者:Gang Li、Patrick A. Kates、Andrew K. Dilger、Peter T. Cheng、William R. Ewing、John T. Groves
    DOI:10.1021/acscatal.9b03457
    日期:2019.10.4
    Enamines and enol ethers are versatile synthons for chemical synthesis. While several methods have been developed to access such molecules, prefunctionalized starting materials are usually required, and direct desaturation methods remain rare. Herein, we report direct desaturation reactions of N-protected cyclic amines and cyclic ethers using a mild I(III) oxidant, PhI(OAc)2, and an electron-deficient
    烯胺和烯醇醚是用于化学合成的通用合成子。尽管已经开发出几种方法来接近这些分子,但是通常需要预官能化的起始材料,并且直接去饱和方法仍然很少。在这里,我们报告了使用温和的I(III)氧化剂PhI(OAc)2和电子不足的五氟苯卟啉Mn(TPFPP)Cl的N-保护的环胺和环醚的直接去饱和反应。该系统显示出各种环状胺和醚的α,β-去饱和的高效率。机理探针表明,去饱和反应是通过最初的α-CH羟基化途径发生的,这可以保护产物免于过氧化。
  • MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS
    申请人:Combs Andrew Paul
    公开号:US20090286778A1
    公开(公告)日:2009-11-19
    The present invention relates to macrocyclic compounds of Formula I: or pharmaceutically acceptable salts thereof or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are JAK/ALK inhibitors useful in the treatment of JAK/ALK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.
    本发明涉及以下化学式I的大环化合物: 或其药用可接受盐或季盐,其中所述成员在此提供,并且它们的组成物和使用方法,这些JAK/ALK抑制剂在治疗JAK/ALK相关疾病中有用,例如炎症和自身免疫性疾病以及癌症。
查看更多

同类化合物

(R)-3-甲基哌啶盐酸盐; (R)-2-苄基哌啶-1-羧酸叔丁酯 ((3S,4R)-3-氨基-4-羟基哌啶-1-基)(2-(1-(环丙基甲基)-1H-吲哚-2-基)-7-甲氧基-1-甲基-1H-苯并[d]咪唑-5-基)甲酮盐酸盐 高氯酸哌啶 高托品酮肟 马来酸帕罗西汀 颜料红48:4 顺式3-氟哌啶-4-醇盐酸盐 顺式2,6-二甲基哌啶-4-酮 顺式1-苄基-4-甲基-3-甲氨基-哌啶 顺式-叔丁基4-羟基-3-甲基哌啶-1-羧酸酯 顺式-6-甲基-哌啶-1,3-二甲酸1-叔丁酯 顺式-5-(三氟甲基)哌啶-3-羧酸甲酯盐酸盐 顺式-4-叔丁基-2-甲基哌啶 顺式-4-Boc-氨基哌啶-3-甲酸甲酯 顺式-4-(氮杂环丁烷-1-基)-3-氟哌 顺式-3-顺式-4-氨基哌啶 顺式-3-甲氧基-4-氨基哌啶 顺式-3-BOC-3,7-二氮杂双环[4.2.0]辛烷 顺式-3-(1-吡咯烷基)环丁腈 顺式-3,5-哌啶二羧酸 顺式-3,4-二溴-3-甲基吡咯烷盐酸盐 顺式-2,6-二甲基-4-氧代哌啶-1-羧酸叔丁基酯 顺式-1-叔丁氧羰基-4-甲基氨基-3-羟基哌啶 顺式-1-boc-3,4-二氨基哌啶 顺式-1-(4-叔丁基环己基)-4-苯基-4-哌啶腈 顺式-1,3-二甲基-4-乙炔基-6-苯基-3,4-哌啶二醇 顺-4-(4-氟苯基)-1-(4-异丙基环己基)-4-哌啶羧酸 顺-4-(2-氟苯基)-1-(4-异丙基环己基)-4-哌啶羧酸 顺-3-氨基-4-氟哌啶-1-羧酸叔丁酯 顺-1-苄基-4-甲基哌啶-3-氨基酸甲酯盐酸盐 非莫西汀 雷芬那辛 雷拉地尔 阿维巴坦中间体4 阿格列汀杂质 阿尼利定盐酸盐 CII 阿尼利定 阿塔匹酮 阿哌沙班杂质BMS-591455 阿哌沙班杂质87 阿哌沙班杂质52 阿哌沙班杂质51 阿哌沙班杂质5 阿哌沙班杂质 阿哌沙班杂质 阿哌沙班-d3 阿哌沙班 阻聚剂701 间氨基谷氨酰胺